AU2020236525B2 - Stable topical compositions of Fenoldopam - Google Patents

Stable topical compositions of Fenoldopam Download PDF

Info

Publication number
AU2020236525B2
AU2020236525B2 AU2020236525A AU2020236525A AU2020236525B2 AU 2020236525 B2 AU2020236525 B2 AU 2020236525B2 AU 2020236525 A AU2020236525 A AU 2020236525A AU 2020236525 A AU2020236525 A AU 2020236525A AU 2020236525 B2 AU2020236525 B2 AU 2020236525B2
Authority
AU
Australia
Prior art keywords
fenoldopam
composition
topical
composition according
topical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2020236525A
Other languages
English (en)
Other versions
AU2020236525A1 (en
Inventor
Avi Avramoff
Vered Rosenberger
Ron Schlinger
Tzviel Sheskin
Helena Shifrin
Alexandra SHRAIFEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taro Pharmaceutical Industries Ltd
Original Assignee
Taro Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taro Pharmaceutical Industries Ltd filed Critical Taro Pharmaceutical Industries Ltd
Publication of AU2020236525A1 publication Critical patent/AU2020236525A1/en
Application granted granted Critical
Publication of AU2020236525B2 publication Critical patent/AU2020236525B2/en
Priority to AU2022202941A priority Critical patent/AU2022202941A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2020236525A 2019-03-08 2020-03-06 Stable topical compositions of Fenoldopam Ceased AU2020236525B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022202941A AU2022202941A1 (en) 2019-03-08 2022-05-03 Stable topical compositions of fenoldopam

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962815893P 2019-03-08 2019-03-08
US62/815,893 2019-03-08
PCT/IB2020/051967 WO2020183322A1 (en) 2019-03-08 2020-03-06 Stable topical compositions of fenoldopam

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022202941A Division AU2022202941A1 (en) 2019-03-08 2022-05-03 Stable topical compositions of fenoldopam

Publications (2)

Publication Number Publication Date
AU2020236525A1 AU2020236525A1 (en) 2021-11-04
AU2020236525B2 true AU2020236525B2 (en) 2022-02-03

Family

ID=69846519

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020236525A Ceased AU2020236525B2 (en) 2019-03-08 2020-03-06 Stable topical compositions of Fenoldopam
AU2022202941A Abandoned AU2022202941A1 (en) 2019-03-08 2022-05-03 Stable topical compositions of fenoldopam

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022202941A Abandoned AU2022202941A1 (en) 2019-03-08 2022-05-03 Stable topical compositions of fenoldopam

Country Status (11)

Country Link
US (2) US11446237B2 (https=)
EP (2) EP3908255B1 (https=)
JP (2) JP7124234B2 (https=)
CN (2) CN116966129A (https=)
AU (2) AU2020236525B2 (https=)
BR (1) BR112021017140A2 (https=)
CA (1) CA3131049A1 (https=)
ES (1) ES2941241T3 (https=)
IL (1) IL286197A (https=)
NZ (1) NZ781774A (https=)
WO (1) WO2020183322A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023257375A1 (en) 2022-04-21 2024-11-07 Glaukos Corporation Ophthalmic topical cream compositions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018042352A1 (en) * 2016-08-31 2018-03-08 Taro Pharmaceutical Industries Fenoldopam topical formulations for treating skin disorders

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
ATE210975T1 (de) 1994-06-23 2002-01-15 Procter & Gamble Topisch anzuwendende zubereitungen enthaltend n- acetyl-l-cystein
US6054429A (en) 1996-03-08 2000-04-25 Elan Pharmaceuticals, Inc. Epidural method of producing analgesia
AU3869399A (en) 1998-04-27 1999-11-16 Elan Pharmaceuticals, Inc. Transdermal administration of fenoldopam
JPH11335236A (ja) 1998-05-22 1999-12-07 Shiseido Co Ltd 皮膚外用剤
EP1100476B1 (en) * 1998-07-24 2004-06-16 ALZA Corporation Formulations for the transdermal administration of fenoldopam
US6699497B1 (en) 1998-07-24 2004-03-02 Alza Corporation Formulations for the transdermal administration of fenoldopam
US7442369B1 (en) * 2000-08-09 2008-10-28 Mcneil Ab Compositions of minoxidil
US7358236B1 (en) 2002-06-21 2008-04-15 Oxigene, Inc. Control of acute hypertension and cardiotoxicity in patients treated with vascular targeting agents
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
WO2005079851A2 (en) 2004-02-18 2005-09-01 Sepracor, Inc. Dopamine-agonist combination therapy with sedatives for improving sleep quality
WO2005108387A2 (en) 2004-05-03 2005-11-17 Boehringer Ingelheim Pharmaceuticals, Inc. Cytokine inhibitors
CN101151028A (zh) * 2005-03-03 2008-03-26 Isw集团公司 局部用凝胶组合物
AU2006265002B2 (en) 2005-06-30 2012-09-20 Centocor, Inc. Anti-IL-23 antibodies, compositions, methods and uses
JP2009502206A (ja) 2005-08-03 2009-01-29 ミニュー・セラピューティクス・リミテッド 腫瘍壊死因子アルファ（ＴＮＦ−α）合成および分泌を調節するための、Ｔ細胞におけるＫｖ１．１電位依存性カリウムチャンネルのモデュレーション、およびＴＮＦ−αの有害な高または低レベルを介しての人の疾患または傷害の治療
WO2009052491A2 (en) 2007-10-18 2009-04-23 Geraghty, Erin Fenoldopam formulations and prodrug derivatives
WO2009072007A2 (en) 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
WO2009076553A1 (en) 2007-12-11 2009-06-18 Monroe Stephen H Composition of aqueous buffer solution for the treatment of cellular environment and ion channels and methods for using same
CA2732439A1 (en) 2008-07-31 2010-02-04 Case Western Reserve University Halogen-stabilized insulin
JP2011144143A (ja) 2010-01-15 2011-07-28 Shiseido Co Ltd 皮膚外用剤
RU2571277C2 (ru) 2010-10-21 2015-12-20 Галдерма С.А. Композиции геля с бримонидином и способы применения
HUE034480T2 (en) 2011-04-28 2018-02-28 Platform Brightworks Two Ltd Improved parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same
FR2991177B1 (fr) 2012-06-01 2014-12-19 Galderma Res & Dev Compositions topiques, contenant un retinoide, de type emulsion huile dans eau sans emulsionnant
AU2014227996B2 (en) * 2013-03-15 2018-08-23 Vapogenix, Inc. Novel analgesic compositions
JP6893075B2 (ja) 2014-08-04 2021-06-23 日東電工株式会社 液性免疫誘導促進用組成物及びワクチン医薬組成物
UA121985C2 (uk) * 2015-01-23 2020-08-25 Др. Редді'З Лабораторіз Лімітед Нефарбуюча гелева композиція для місцевого застосування, яка містить німесулід
MX2020004187A (es) * 2017-10-24 2020-09-21 Glenmark Pharmaceuticals Ltd Composicion farmaceutica topica de adapaleno y minociclina.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018042352A1 (en) * 2016-08-31 2018-03-08 Taro Pharmaceutical Industries Fenoldopam topical formulations for treating skin disorders

Also Published As

Publication number Publication date
EP4218719A2 (en) 2023-08-02
EP3908255B1 (en) 2023-01-11
WO2020183322A1 (en) 2020-09-17
ES2941241T3 (es) 2023-05-19
JP2022160648A (ja) 2022-10-19
CN113543773B (zh) 2023-07-14
EP3908255A1 (en) 2021-11-17
BR112021017140A2 (pt) 2021-11-09
US20230059107A1 (en) 2023-02-23
AU2022202941A1 (en) 2022-05-26
EP4218719A3 (en) 2023-09-20
US11446237B2 (en) 2022-09-20
CN116966129A (zh) 2023-10-31
JP2022515569A (ja) 2022-02-18
CA3131049A1 (en) 2020-09-17
IL286197A (en) 2021-10-31
NZ781774A (en) 2023-03-31
CN113543773A (zh) 2021-10-22
AU2020236525A1 (en) 2021-11-04
JP7124234B2 (ja) 2022-08-23
US20220040089A1 (en) 2022-02-10

Similar Documents

Publication Publication Date Title
JP7324210B2 (ja) トファシチニブを含む局所製剤
CA3102689C (en) Method and formulation for improving roflumilast skin penetration lag time
US20130116271A1 (en) Tacrolimus-containing oil-in-water type creamy composition
US20230059107A1 (en) Stable topical compositions of fenoldopam
WO2023016583A1 (zh) 一种芦可替尼组合物及其用途
TWI729371B (zh) 治療搔癢症的組合物與方法
US10342774B2 (en) Topical pharmaceutical composition of acitretin
JP5033381B2 (ja) 外用医薬組成物
JP5460766B2 (ja) 外用医薬組成物
WO2007086582A1 (ja) ２２－オキサ－１α,２５－ジヒドロキシビタミンＤ3を含有する水中油型乳剤性ローション剤およびそれを用いた皮膚疾患の治療方法
EP3666254B1 (en) Pharmaceutical composition containing (r)-n-[1-(3,5-difluoro-4-methansulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide
US20240299422A1 (en) Topical Cannabinoid Compositions and Methods for Treating Skin Diseases
CA3174475A1 (en) Topical pharmaceutical formulations of a cyclic depsipeptide
KR20000066357A (ko) 케토롤락 외용제제

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired